Prellis Biologics

42 employees

Prellis employs holographic tissue printing technology with fully human antibody discovery, in vitro human disease and ADME/Tox models.

Basic info

Industry

biotechnology research

Sectors

3D Printing

Biotechnology

Immunogenicity Screening

Lymph Node Organoids

Therapeutics

Human Antibody Discovery

Camelid Antibodies

Biopharma

Antibody Discovery

Date founded

2016

Funding rounds raised

Total raised

$35M

from 22 investors over 22 rounds

Prellis Biologics raised $35M on August 10, 2022

Investors: IndieBio, True Ventures, Lucas Venture Group, Khosla Ventures, Black Diamond Ventures, Avidity Partners, WRVI Capital and SOSV - The Accelerator VC

Prellis Biologics raised $19M on July 14, 2021

Investors: SOSV - The Accelerator VC

Prellis Biologics raised undisclosed on June 14, 2021

Investors: SOSV - The Accelerator VC

Prellis Biologics raised undisclosed on April 16, 2020

Investors: IndieBio and SOSV - The Accelerator VC

Prellis Biologics raised $8.7M on March 21, 2019

Investors: IndieBio, True Ventures and Khosla Ventures

Prellis Biologics raised undisclosed on March 7, 2018

Investors: IndieBio, Cantos Ventures and SOSV - The Accelerator VC

Prellis Biologics raised $1.8M on September 13, 2017

Investors: True Ventures and Civilization Ventures

Prellis Biologics raised $120K on April 19, 2017